Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:10 PM
Ignite Modification Date:
2025-12-24 @ 7:10 PM
NCT ID:
NCT00467103
Eligibility Criteria:
Inclusion Criteria:
* Aphasia patients with a single, unilateral, left hemisphere stroke.
* Patients must be native speakers of English
* Patients must be at least 6 months poststroke and produce mild-severe nonfluent speech. Minimum Language requirements: 2-4 word phrase length on elicited propositional speech
* Auditory Comprehension a the 25th percentile or higher on the BDAE subtests for Word Comprehension and Commands, sufficient to cooperate during testing
* The ability to name a minimum of 3 items on the Boston Naming Test at entry into study.
* Patients must understand the nature of the study and give informed consent.
* Normal right-handed controls with no history of neurological disease or substance abuse; age, education and gender-matched to the Aphasia cases.
Exclusion Criteria:
* Patients with more than one stroke in the left hemisphere or patients with bilateral strokes.
* Each participant must be able to have an MRI scan.
* MRI is contraindicated for pregnant women.
* Patients will be excluded if they have the following:
* Intracranial metallic bodies from prior neurosurgical procedure, implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit or ventriculoperitoneal shunt
* Past history of seizures within one year or unexplained loss of consciousness Family history of epilepsy
* Acute, unstable medical conditions
* History of substance abuse (within last 6 months)
* Abnormal neurological exam, other than as signs of the condition being studied
* Abnormal MRI, or history of known structural brain abnormality other than as signs of the condition studied in the present protocol.
* Administration of investigational drug within 5 halflives of the drug prior to testing.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
45 Years
Maximum Age:
80 Years
Study:
NCT00467103
Study Brief:
Protocol Section:
NCT00467103